ReviewJournal of clinical medicine2021
Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06436768 (Effectiveness of Sugammadex Versus Neostigmine on the Reversal of Rocuronium-induced Neuromuscular Blockade in Patients With Myasthenia Gravis After Thoracoscopic Thymectomy), which is not on this map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness of Sugammadex Versus Neostigmine on the Reversal of Rocuronium-induced Neuromuscular Blockade in Patients With Myasthenia Gravis After Thoracoscopic Thymectomy: A Multicenter Randomized Controlled Trial
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Diabetes mellitus in patients with myasthenia gravis: a systematic review and meta-analysis.Endocrine · 2025Pooled it
- Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review.Frontiers in neurology · 2022Pooled it
- Statins and Myasthenia Gravis: Clinical Implications and Pathogenesis.International journal of molecular sciences · 2026Review
- Review
- Navigating Anxiety Management in Myasthenia Gravis Crisis With Prolonged Corrected QT (QTc): A Case Report.Cureus · 2026Article
- Women and Myasthenia Gravis.Annals of Indian Academy of Neurology · 2026Article
- Management of suicidal crisis in an adolescent with Becker muscular dystrophy: a case report.BMC psychiatry · 2026Article
- Italian recommendations for the diagnosis and treatment of myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Associated Autoimmunity in Myasthenia Gravis in Denmark: A Nationwide Case-Control Study.European journal of neurology · 2026Article
- Inappropriate Antimicrobial Regimen Leading to RecurrentInfection and drug resistance · 2026Article
- Case Report: Thymoma-associated stiff person syndrome and myasthenia gravis: an index case with exploratory exome sequencing and review of reported cases.Frontiers in oncology · 2026Article
- Beyond numbers: challenges in assessing myasthenia gravis prevalence in inflammatory bowel disease.Arquivos de neuro-psiquiatria · 2026Article
- Late-Onset Ocular Myasthenia Gravis-Like Symptoms During Erenumab Therapy for Chronic Migraine: A Case Report.Biologics : targets & therapy · 2026Article
- Article
- Diagnosis and management of acute neuromuscular weakness.Singapore medical journal · 2026Article
- Myasthenia Gravis Outcomes After Use of Statins and Other Contraindicated Treatments: Results From the French National Insurance Database.European journal of neurology · 2026Observational
- Multiple concurrent opportunistic infections in patient with myasthenia gravis: A case report.Virulence · 2025Article
- Article
- Article
- Persistent Jaw Drop Following Botulinum Injection as the Initial Clinical Manifestation of Spinal and Bulbar Muscular Atrophy.Journal of clinical neurology (Seoul, Korea) · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder which is characterized by presence of antibodies against acetylcholine receptors (AChRs) or other proteins of the postsynaptic membrane resulting in damage to postsynaptic membrane, decreased number of AChRs or blocking of the receptors by autoantibodies. A number of drugs such as immune checkpoint inhibitors, penicillamine, tyrosine kinase inhibitors and interferons may induce de novo MG by altering the immune homeostasis mechanisms which prevent emergence of autoimmune diseases such as MG. Other drugs, especially certain antibiotics, antiarrhythmics, anesthetics and neuromuscular blockers, have deleterious effects on neuromuscular transmission, resulting in increased weakness in MG or MG-like symptoms in patients who do not have MG, with the latter usually being under medical circumstances such as kidney failure. This review summarizes the drugs which can cause de novo MG, MG exacerbation or MG-like symptoms in nonmyasthenic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.